Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #9245
Ace Report Cover Metabolic Disorders

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates


Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Contributing Authors: PD Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasi...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.